Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJonathan L. KaufmanMPMichel PavicPMPatrick J. Mueller

Discussion

Loading...

Member takes

Overview

Phase 1b trial revealed combination therapy significantly improves response rates in relapsed multiple myeloma patients, indicating potential treatments.

Key Points

  • To evaluate the safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma.
  • Phase 1b, open-label, multicenter trial assessing combination therapy
  • Patients aged ≥18 with relapsed or refractory multiple myeloma received elranatamab and iberdomide
  • Primary endpoint focused on dose-limiting toxicities and secondary endpoints assessed adverse events and response rates.
  • Of 22 patients, the overall response rate was 90.9% with 45.5% achieving complete response
  • Treatment-emergent adverse events occurred in 100% of patients, with neutropenia and cytokine release syndrome being frequent
  • The study showed a favorable safety profile while evaluating treatment durations.

Cite This Study

Kaufman et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d051https://doi.org/10.1182/blood-2025-100
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025
  2. 2Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025 · 3 citations
  3. 3Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025
  4. 4Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis2025
  5. 5Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial2025 · 1 citations